ESMO Preceptorship on Uterine Cancer 2024: Lugano
Do not miss this opportunity: apply now!
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Members of the ESMO GI 2024 Scientific Committee and global gastrointestinal cancers experts provide compelling reasons why attending this event is crucial.
Secure your place for the second webinar in this new, vibrant series and learn how standardised primary data can improve patient outcomes.
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and have your questions answered by the experts developing and implementing the ESMO Guidelines
Experience the forefront of Asian and global oncology at ESMO Asia 2024, 6-8 December, Singapore. Connect, learn, and innovate in multidisciplinary cancer care.
Registration for the ESMO Academy 2024 is now open. Get your update on the key topics in medical oncology.
Gain deeper understanding and register for the ESMO Deep Dive: Breast Cancer webinar, available to all ESMO members.
Save the date for a unique opportunity to connect with world renowned experts discussing the latest trials in advanced breast cancer and high-risk GIST
These annual four-day residential courses provide insight into the field of medical oncology, enabling participants to get a better picture before making the choice of their specialisation
This updated edition provides an up-to-date overview of the current treatment options and what future developments are on the horizon in the fast-developing field of lymphomas.
The living guideline is directly linked to ESMO-MCBS scores and references, easily accessible on desktop and mobile devices
Do not miss this opportunity: apply now!
Submit your abstract for #EMUC24 & get ready to access the latest advancements in #GUcancers
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Explore ESMO's new proposal for a classification of tissue-agnostic therapeutics
ESMO would like to thank the Gyógyulj Velünk Egyesület (GYVE) for providing translation in the Hungarian language
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
Additional safety information regarding the risk of serious adverse reactions related to fluorouracil use in patients with DPD deficiency became available since its approval
Expanding the guide’s availability in more languages
Findings from the ALINA study
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Findings from the NRG Oncology/GOG Study 279
Expanding the guide’s availability in more languages
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
Additional safety information regarding the risk of serious adverse reactions related to fluorouracil use in patients with DPD deficiency became available since its approval
Findings from the ALINA study
Findings from the NRG Oncology/GOG Study 279
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
Better risk counselling may be achieved using the mathematical model
Evidence for efficacy is based on the results from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies
Findings from a pooled analysis of clinical trials conducted in patients with high-risk resectable melanoma
Findings from a systematic review and meta-analysis
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
As the world observes Universal Health Coverage Day, ESMO anticipates the results of the latest study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines, highlighting a worrying stall over the last five years
The ESMO Award for Immuno-Oncology 2023 was bestowed to Steven A. Rosenberg in recognition of his exceptional contribution to the field of cancer immunology research.
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
Universal health coverage in oncology is still not a reality, as a recent report shows
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.